Regeneron Pharmaceuticals, Inc. (REGN)
- Previous Close
890.68 - Open
881.72 - Bid 881.96 x 100
- Ask 883.38 x 100
- Day's Range
875.22 - 887.48 - 52 Week Range
684.81 - 998.33 - Volume
502,941 - Avg. Volume
467,063 - Market Cap (intraday)
96.942B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
25.38 - EPS (TTM)
34.80 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,051.33
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
www.regeneron.comRecent News: REGN
Performance Overview: REGN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REGN
Valuation Measures
Market Cap
96.94B
Enterprise Value
88.80B
Trailing P/E
25.40
Forward P/E
19.65
PEG Ratio (5yr expected)
1.42
Price/Sales (ttm)
7.66
Price/Book (mrq)
3.73
Enterprise Value/Revenue
6.77
Enterprise Value/EBITDA
18.92
Financial Highlights
Profitability and Income Statement
Profit Margin
30.14%
Return on Assets (ttm)
8.49%
Return on Equity (ttm)
16.26%
Revenue (ttm)
13.12B
Net Income Avi to Common (ttm)
3.95B
Diluted EPS (ttm)
34.80
Balance Sheet and Cash Flow
Total Cash (mrq)
10.84B
Total Debt/Equity (mrq)
10.74%
Levered Free Cash Flow (ttm)
2.76B
Research Analysis: REGN
Company Insights: REGN
REGN does not have Company Insights